More Than 200 Companies Advance Trial Management with Veeva CTMS
Veeva Systems (NYSE: VEEV) announced that over 200 companies, including 17 of the top 20 biopharmas, are now using Veeva CTMS for clinical trial management. The platform helps streamline trial processes and enhance collaboration as studies become more complex and data-intensive.
The system serves as a central hub for managing study metrics and documents, enabling both insourced and outsourced trial operations while maintaining compliance with global regulations like ICH E6(R2) and (R3). New features include automated CRO-to-sponsor data transfers, improved oversight issue tracking, and enhanced capabilities for managing complex trials.
Veeva CTMS is part of the broader Veeva Clinical Platform, designed to accelerate trial execution and improve operational efficiency. The company continues to enhance the platform through three product releases annually.
Veeva Systems (NYSE: VEEV) ha annunciato che oltre 200 aziende, tra cui 17 delle 20 principali biopharmaceutiche, stanno ora utilizzando Veeva CTMS per la gestione dei trial clinici. La piattaforma aiuta a semplificare i processi dei trial e a migliorare la collaborazione man mano che gli studi diventano più complessi e ricchi di dati.
Il sistema funge da hub centrale per la gestione dei metrici e dei documenti degli studi, consentendo sia operazioni di trial interne che esterne pur mantenendo la conformità con le normative globali come ICH E6(R2) e (R3). Le nuove funzionalità includono trasferimenti di dati automatizzati dal CRO agli sponsor, tracciamento migliorato delle problematiche di supervisione e capacità potenziate per gestire trial complessi.
Veeva CTMS fa parte della più ampia Veeva Clinical Platform, progettata per accelerare l'esecuzione dei trial e migliorare l'efficienza operativa. L'azienda continua a migliorare la piattaforma attraverso tre rilasci di prodotti all'anno.
Veeva Systems (NYSE: VEEV) anunció que más de 200 compañías, incluyendo 17 de las 20 principales biofarmacéuticas, están utilizando Veeva CTMS para la gestión de ensayos clínicos. La plataforma ayuda a agilizar los procesos de ensayo y a mejorar la colaboración a medida que los estudios se vuelven más complejos y ricos en datos.
El sistema sirve como un centro central para gestionar métricas y documentos de estudio, permitiendo operaciones de ensayo tanto internas como externas, mientras se mantiene la conformidad con regulaciones globales como ICH E6(R2) y (R3). Las nuevas características incluyen transferencias de datos automatizadas del CRO al patrocinador, seguimiento mejorado de problemas de supervisión y capacidades mejoradas para gestionar ensayos complejos.
Veeva CTMS es parte de la plataforma amplia Veeva Clinical Platform, diseñada para acelerar la ejecución de ensayos y mejorar la eficiencia operativa. La empresa continúa mejorando la plataforma a través de tres lanzamientos de productos anuales.
Veeva Systems (NYSE: VEEV)는 200개 이상의 기업, 그 중 20대 바이오 제약사는 17개가 Veeva CTMS를 임상 시험 관리에 사용하고 있다고 발표했습니다. 이 플랫폼은 연구가 점점 더 복잡하고 데이터 집약적이 됨에 따라 시험 프로세스를 간소화하고 협업을 향상시키는 데 도움을 줍니다.
이 시스템은 연구 지표 및 문서를 관리하기 위한 중앙 허브 역할을 하며, 내부 및 외부 시험 운영을 모두 허용하면서 ICH E6(R2) 및 (R3)와 같은 글로벌 규정을 준수하게 유지합니다. 새로운 기능에는 자동화된 CRO-스폰서 데이터 전송, 개선된 감독 문제 추적 및 복잡한 시험 관리를 위한 향상된 기능이 포함됩니다.
Veeva CTMS는 시험 실행을 가속화하고 운영 효율성을 개선하기 위해 설계된 Veeva Clinical Platform의 일부입니다. 이 회사는 연간 세 번의 제품 출시를 통해 플랫폼을 지속적으로 개선하고 있습니다.
Veeva Systems (NYSE: VEEV) a annoncé que plus de 200 entreprises, dont 17 des 20 plus grandes biopharmaceutiques, utilisent désormais Veeva CTMS pour la gestion des essais cliniques. La plateforme aide à rationaliser les processus d'essai et à améliorer la collaboration à mesure que les études deviennent plus complexes et axées sur les données.
Le système sert de hub central pour la gestion des métriques et des documents d'étude, permettant des opérations d'essai tant internes qu'externes tout en maintenant la conformité avec les réglementations mondiales telles que l'ICH E6(R2) et (R3). Les nouvelles fonctionnalités incluent des transferts de données automatisés du CRO vers le sponsor, un suivi amélioré des problèmes de supervision et des capacités renforcées pour la gestion des essais complexes.
Veeva CTMS fait partie de la plateforme clinique plus large de Veeva, conçue pour accélérer l'exécution des essais et améliorer l'efficacité opérationnelle. L'entreprise continue d'améliorer la plateforme grâce à trois lancements de produits par an.
Veeva Systems (NYSE: VEEV) gab bekannt, dass über 200 Unternehmen, darunter 17 der 20 größten Biopharmaunternehmen, Veeva CTMS für das Management klinischer Studien nutzen. Die Plattform hilft dabei, die Abläufe der Studien zu optimieren und die Zusammenarbeit zu verbessern, während die Studien komplexer und datenintensiver werden.
Das System dient als zentrales Zentrum zur Verwaltung von Studienmetriken und -dokumenten, ermöglicht sowohl interne als auch externe Studienoperationen und sorgt dafür, dass die Einhaltung globaler Vorschriften wie ICH E6(R2) und (R3) gewahrt bleibt. Neue Funktionen umfassen automatisierte Datenübertragungen von CRO zu Sponsor, verbessertes Problemmtracking und erweiterte Möglichkeiten zur Verwaltung komplexer Studien.
Veeva CTMS ist Teil der umfassenderen Veeva Clinical Platform, die darauf abzielt, die Durchführung von Studien zu beschleunigen und die operationale Effizienz zu verbessern. Das Unternehmen verbessert die Plattform weiterhin durch drei Produktveröffentlichungen pro Jahr.
- Strong market penetration with 200+ companies using the CTMS platform
- High-value customer base including 85% of top 20 biopharmas
- Regular platform updates with three annual releases
- New feature rollouts addressing key operational needs
- None.
Insights
The announcement that 200+ companies, including 17 of the top 20 biopharmas, have adopted Veeva CTMS represents a significant market leadership position in the clinical trial management space. This level of penetration among major pharmaceutical companies creates a powerful network effect that could accelerate further adoption across the industry.
The new CTMS features address critical industry challenges: automated CRO data transfers tackle the growing complexity of sponsor-CRO relationships, while enhanced oversight capabilities align with evolving ICH E6(R3) regulatory requirements. These developments position Veeva strategically in the $2+ billion clinical trial software market.
Three key implications stand out:
- The high adoption rate among top biopharmas creates significant switching costs, potentially leading to stable, recurring revenue streams
- Veeva's three-releases-per-year cadence demonstrates strong R&D investment and ability to rapidly adapt to market needs
- The platform's flexibility to support both insourced and outsourced trials addresses a important market need as companies increasingly adopt hybrid trial operating models
With clinical trial complexity increasing and regulatory requirements evolving, Veeva's position as the central hub for trial management suggests continued strong growth potential in its clinical operations business segment.
Biopharmas use leading CTMS for improved trial efficiency and collaboration
"Veeva CTMS is the central hub of our trials, allowing study metrics and documents to flow seamlessly across our ecosystem," said Bonne Adams, vice president of operations at Inhibrx. "Using clinical applications on a connected platform saves time and effort for our lean team and improves how we work with CRO partners."
Whether biopharmas insource or outsource trials, clinical teams can use Veeva CTMS to proactively manage studies and quickly identify and address issues. With a flexible and scalable system, companies can accelerate trial execution and deliver high-quality data while maintaining compliance with global regulations like ICH E6(R2) and (R3).
To help biopharmas adapt to trial operating model changes and keep up with evolving regulations, Veeva continues to deliver clinical innovations. New Veeva CTMS advancements include:
- CTMS transfer automates daily data transfers from CROs to sponsors for greater visibility
- Oversight issue tracking and management for faster resolution
- Enhancements to manage insourced, outsourced, and complex trials for speed and agility
"Modern clinical trial management systems should scale easily and support both insourced and outsourced operating models," said Henry Galio, vice president of Veeva CTMS strategy. "To provide this flexibility, we're delivering new capabilities for Veeva CTMS through our three product releases per year, continuously advancing to help the industry work better together and accelerate execution."
With the increased adoption of Veeva CTMS, more companies are simplifying trial operations and maintaining compliance regardless of operating model. Veeva CTMS is part of Veeva Clinical Platform, the most complete and highest-quality platform for faster and more efficient trials. Learn more about Veeva CTMS at SCOPE 2025 booth 916, Feb. 3-6 in
Additional Information
For more on Veeva CTMS, visit: veeva.com/CTMS Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-200-companies-advance-trial-management-with-veeva-ctms-302362835.html
SOURCE Veeva Systems
FAQ
How many companies are currently using Veeva CTMS for trial management?
What are the key new features added to Veeva CTMS in 2025?
How often does Veeva (VEEV) release updates for its CTMS platform?
What regulatory compliance standards does Veeva CTMS support?
How does Veeva CTMS benefit clinical trial operations?
